Skip to main content
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · ORMP ISIN · US68403P2039 LEI · 5299006K52ZIIGQJ6R84 TA Manufacturing
Open in API
Filings indexed 1,576 across all filing types
Latest filing 2023-12-19 Board/Management Inform…
Country US United States of America
Listing TA ORMP

About Oramed Pharmaceuticals Inc.

https://www.oramed.com

Oramed Pharmaceuticals Inc. is a clinical-stage company focused on developing oral drug delivery systems for medications that are typically administered via injection. The company's core technology is its proprietary Protein Oral Delivery (POD™) platform, which is designed to protect therapeutic proteins from enzymatic degradation in the gastrointestinal tract and enhance their absorption into the bloodstream. Oramed's lead product candidate is an oral insulin capsule (ORMD-0801) for the treatment of diabetes. The company's pipeline also includes an oral GLP-1 analog capsule (ORMD-0901) for type 2 diabetes. Oramed aims to improve patient compliance, comfort, and therapeutic outcomes by converting injectable treatments into oral formulations.

Recent filings

Filing Released Lang Actions
Form 8-K - Director Appointment- Dr. Daniel Aghion, effective as of January 1, 2024.
Board/Management Information Classification · 99% confidence The document is explicitly titled "FORM 8-K" and is a "CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934". The content under Item 5.02 details the appointment of a new director, Dr. Daniel Aghion, effective January 1, 2024. This type of filing, reporting material, current events like officer/director changes, is a standard SEC filing. While the content relates to Board/Management information (MANG) and potentially Remuneration (DEF 14A), the overarching regulatory filing type is the Form 8-K. Since Form 8-K is not explicitly listed as a primary code, and it is a mandatory, periodic/current disclosure, it falls best under the general regulatory filing category, RNS, or potentially a specific SEC filing code if available. Given the provided definitions, and recognizing that Form 8-K is a general current report, it does not fit perfectly into the specialized categories like 10-K (Annual Report) or ER (Earnings Release). However, the content specifically addresses a change in the Board of Directors (Item 5.02), which aligns closely with the description for Board/Management Information (MANG). Since the document is the full report itself (not an announcement of a report), MANG is the most specific content-based classification available among the choices, even though the wrapper is an 8-K. If 8-K were an option, it would be preferred, but MANG captures the substance of Item 5.02.
2023-12-19 English
Form 8-K - Director Appointment- Dr. Daniel Aghion, effective as of January 1, 2024.
Board/Management Information Classification · 98% confidence The document explicitly states it is an 'Other Report or Announcement' under Israeli regulation and attaches a report titled '*Form 8-K - Director Appointment*'. The content concerns the appointment of a director (Daniel Aghion). According to the definitions, announcements regarding changes in the company's board of directors or senior management fall under 'Board/Management Information' (MANG). Although it references a Form 8-K, which is a US SEC filing, the context here is the announcement of that event, not the full 10-K or a general regulatory filing fallback, as a specific category exists for management changes.
2023-12-19 English
CURRENT REPORT
Regulatory Filings
2023-12-18 English
Form 10-Q - Q3 2023
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q filed with the U.S. Securities and Exchange Commission by Oramed Pharmaceuticals Inc. for the quarterly period ended September 30, 2023. It contains comprehensive financial statements, management's discussion and analysis (MD&A), and other required disclosures. According to the filing definitions, a comprehensive financial report for a period shorter than a full fiscal year is classified as an Interim / Quarterly Report (IR). Q3 2023
2023-11-09 English
Form 10-Q - Q3 2023
Report Publication Announcement Classification · 100% confidence The document is a short notification (1905 characters) from the Israel Securities Authority (MAGNA system) that explicitly states 'Attached hereto is a report on Form 10-Q - Q3 2023'. Per the 'Menu vs Meal' rule, since this is an announcement of a report rather than the report itself, it is classified as a Report Publication Announcement (RPA). Q3 2023
2023-11-09 English
QUARTERLY REPORT
Interim / Quarterly Report 9M 2023
2023-11-09 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.